Alnylam Pharma (ALNY) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
May 5, 2017 10:07 AM EDTChardan Capital Markets lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $95.00 (from $97.00) while maintaining a Buy rating following Q1 results.
Analyst Madhu Kumar commented, "Alnylam's lead asset, patisiran, a RNAi drug targeting transthyretin (TTR), is currently in the phase III APOLLO... More
